A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) among healthy Chinese men. The tolerance, immunogenicity, and pharmacokinetics (PK) of the three drugs were also investigated.Me...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Hong Zhang, Hong Wang, Haijing Wei, Hong Chen, Jingrui Liu, Cuiyun Li, Xiaoxue Zhu, Xiaojiao Li, Jinchen Yu, Yinbo Zhou, Xiaolei Yang, Zhaohe Wang, Min Wu, Yanhua Ding
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2021-01-01
Цуврал:	Frontiers in Pharmacology
Нөхцлүүд:	tocilizumab biosimilar immunogenicity pharmacokinetics intersubject variability tolerance variability
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fphar.2020.609522/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!